There is nothing in these supplementary estimates this year on the Patented Medicine Prices Review Board. My recollection was that there had been, after years of steady state operation, a significant shift, or a significant increase, in the number of contested proceedings that were taking place before that board, and that the amount in the estimates was really meant to deal with that workload increase. My sense is that has ameliorated the situation.
On December 2nd, 2009. See this statement in context.